An official website of the United States government
Publication Information
Affiliation
Benaroya Research Institute at Virginia Mason, 1201 9th Ave, Seattle, WA 98101, USA. cjgreen@benaroyaresearch.org
Authors
Atkinson M, Babu S, Cuthbertson D, DPT-1 study group, Eisenbarth G, Greenbaum CJ, Krischer J, Orban T, Schatz D, Wasserfall C, Yu L, Zeidler A
Studies
Citation
Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz D, Zeidler A, Orban T, Wasserfall C, Cuthbertson D, Krischer J, DPT-1 study group. High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial--Type 1 Diabetes. Diabetologia 2005 Jan;48(1):68-74. Epub 2004 Dec 16.Abstract
Immunological and genetic markers can be used to assess risk of developing type 1 diabetes prior to the onset of clinical symptoms. Autoantibody-positive relatives of patients with type 1 diabetes are at increased risk for disease, while the presence of HLA DQA1*0102/DQB1*0602 is thought to confer protection. Using the unique population identified by the Diabetes Prevention Trial--Type Diabetes (DPT-1), our aim was to determine if these individuals were protected from type 1 diabetes.